Island Pharmaceuticals Limited
Research Island Pharmaceuticals Limited (ILA.AX) on Bullrun: market cap AUD 94.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerILA.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 94.75M
- Financial periodFY2026
- RevenueAUD 282.66K
- Net income-AUD 9.84M
- Free cash flow-AUD 5.68M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 94.75M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 282.66K | -AUD 9.84M | -AUD 5.68M | 100.0% | n/a | AUD 12.87M | n/a | AUD 13.46M |
| FY2025 | n/a | n/a | n/a | n/a | -0.02 | n/a | n/a | n/a |
| FY2024 | AUD 1.25M | -AUD 2.86M | -AUD 3.16M | 100.0% | -0.03 | AUD 1.66M | AUD 421.97K | AUD 1.52M |
| FY2023 | AUD 11.07K | -AUD 2.83M | -AUD 2.70M | 100.0% | -0.03 | AUD 2.00M | n/a | AUD 1.79M |
| FY2022 | n/a | -AUD 2.61M | -AUD 1.88M | n/a | -0.03 | AUD 4.79M | n/a | AUD 4.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-10 | AUD 94.75M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Island Pharmaceuticals Limited's market cap?
Island Pharmaceuticals Limited's market capitalization is AUD 94.75M.
What does Island Pharmaceuticals Limited do?
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.